The study found that there were fewer transplant-related deaths for matched peripheral blood and bone marrow transplants (27 percent and 26 percent, respectively) than as for mismatched peripheral blood, bone marrow, and cord blood transplants (42 percent, 37 percent, and 41 percent, respectively). Leukemia-free survival (LFS) and overall survival (OS) were highest after transplantation of matched peripheral blood (LFS: 43 percent; OS: 45 percent) and bone marrow (LFS: 46 percent; OS: 48 percent). These rates were lower after transplantation of mismatched peripheral blood (LFS: 33 percent; OS: 36 percent), bone marrow (LFS: 34 percent; OS: 38 percent), and cord blood (LFS: 33 percent; OS: 35 percent). Importantly, rates of transplant-related deaths, leukemia-free survival, and overall survival for the three types of mismatched transplants were similar even though cord blood transplants were mismatched at more HLA loci.
Notch-Mediated Expansion of Human Cord Blood Progenitor Cells Results in Rapid Myeloid Reconstitution in Vivo Following Myeloablative Cord Blood Transplantation [Abstract #212]
Colleen Delaney, MD, Fred Hutchinson Cancer Research Center, Seattle, WA
This phase I study found that cord blood that is cultured to increase the number of CD34+ stem cells prior to transplantation helped to decrease the time to engraftment in patients with acute myeloid leukemia.
Cord blood is a valuable source of hematopoietic stem cells as it has a higher concentration of these cells than is normally found in adult blood. However, as only a small quantity of blood can typically be obtained from an umbilical cord, resulting in fewer available
|Contact: Laura Stark|
American Society of Hematology